LB Pharmaceuticals aims to show that what is old can become new again with a lead drug candidate that’s a modified version of a decades-old schizophrenia medication from Sanofi. The strategy is ...

Invea Therapeutics, a biotech company developing drugs for conditions such as psoriasis, has filed for an IPO on the Nasdaq stock exchange. It ...

MapLight Therapeutics is hoping to raise up to $262 million from its IPO, with the proceeds earmarked for its challenger to Bristol Myers Squibb’s schizophrenia med Cobenfy. The California-based ...

Many drugs are available for schizophrenia, but insufficient efficacy and intolerable side effects leave an unmet need that biotech companies are still trying to fill. LB Pharmaceuticals is not ...

(Bloomberg) -- Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

In biotech, capital is a lifeline. Scientific progress alone doesn’t bring therapies to patients; sustained funding helps. With long development timelines and high burn rates, biotech companies must ...

Biotech is one of America’s most critical innovation sectors, but it is facing serious headwinds. Since COVID-19, the industry has been hammered by falling investor confidence, sluggish IPO markets, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Beverly biotech is working ...